Literature DB >> 15105131

Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect.

Jee H Shin1, Ka Y Choi, Yu C Kim, Myung G Lee.   

Abstract

The dose-dependent pharmacokinetics of itraconazole after intravenous (10, 20, or 30 mg/kg) and oral (10, 30, or 50 mg/kg) administration and the first-pass effects of itraconazole after intravenous, intraportal, intragastric, and intraduodenal administration at a dose of 10 mg/kg were evaluated in rats. After intravenous administration at a dose of 30 mg/kg, the area under the plasma concentration-time curve from time zero to infinity (AUC(0- infinity )) was significantly greater than those at 10 and 20 mg/kg (1,090, 1,270, and 1,760 micro g. min/ml for 10, 20, and 30 mg/kg, dose-normalized at 10 mg/kg). After oral administration, the AUC(0- infinity ) was significantly different for three oral doses (380, 687, and 934 micro g. min/ml for 10, 30, and 50 mg/kg, respectively, dose-normalized at 10 mg/kg). The extent of absolute oral bioavailability (F) was 34.9% after an oral dose at 10 mg/kg. The AUC(0- infinity ) (or AUC(0-8 h)) values were comparable between intravenous and intraportal administration and between intragastric and intraduodenal administration, suggesting that the hepatic and gastric first-pass effects were almost negligible in rats. However, the AUC(0-8 h) values after intraduodenal and intragastric administration were significantly smaller than that after intraportal administration, approximately 30%, suggesting that the intestinal first-pass effect was approximately 70% of that of an oral dose of 10 mg/kg. The low F after oral administration of itraconazole at a dose of 10 mg/kg could be mainly due to the considerable intestinal first-pass effect.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105131      PMCID: PMC400537          DOI: 10.1128/AAC.48.5.1756-1762.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Intestinal first-pass effect of bumetanide in rats.

Authors:  E J Kim; K S Han; M G Lee
Journal:  Int J Pharm       Date:  2000-01-25       Impact factor: 5.875

2.  Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique.

Authors:  H J Shim; E J Lee; S H Kim; S H Kim; M Yoo; J W Kwon; W B Kim; M G Lee
Journal:  Biopharm Drug Dispos       Date:  2000-10       Impact factor: 1.627

3.  Dose-independent pharmacokinetics of a candidate for diabetic neuropathy, SR-4668, after intravenous and oral administration to rats: Intestinal first-pass effect.

Authors:  Eun J Kim; Soo K Bae; Hee J Kim; Yoon G Kim; Sun-O Kim; Dong H Lee; Hong Lim; Myung G Lee
Journal:  J Pharm Sci       Date:  2003-05       Impact factor: 3.534

4.  Dose-independent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.

Authors:  Mi H Lee; Soo K Bae; Eun J Kim; Yoon G Kim; Sun-O Kim; Dong H Lee; Hong Lim; Sung-E Yoo; Myung G Lee
Journal:  J Pharm Sci       Date:  2003-01       Impact factor: 3.534

5.  Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: intestinal first-pass effect.

Authors:  Soo K Bae; Won-Suk Chung; Eun J Kim; Jae K Rhee; Jong W Kwon; Won B Kim; Myung G Lee
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

6.  Dose-independent pharmacokinetics of a new reversible proton pump inhibitor, KR-60436, after intravenous and oral administration to rats: gastrointestinal first-pass effect.

Authors:  Su Yeon Yu; Soo Kyung Bae; Eun Jung Kim; Yoon Gyoon Kim; Sun-Ok Kim; Dong Ha Lee; Hong Lim; Myung Gull Lee
Journal:  J Pharm Sci       Date:  2003-08       Impact factor: 3.534

7.  Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.

Authors:  So Hee Kim; Myung Gull Lee
Journal:  Life Sci       Date:  2002-02-01       Impact factor: 5.037

8.  Gastrointestinal first-pass effect of furosemide in rats.

Authors:  E J Kim; K S Han; M G Lee
Journal:  J Pharm Pharmacol       Date:  2000-11       Impact factor: 3.765

9.  Gastrointestinal first-pass effect of YJA-20379-8, a new reversible proton pump inhibitor, in rats.

Authors:  J Kim; E J Kim; K S Han; M S Chang; M G Lee
Journal:  J Pharm Pharmacol       Date:  1999-09       Impact factor: 3.765

10.  Effects of cysteine on the pharmacokinetics of itraconazole in rats with protein-calorie malnutrition.

Authors:  Ae K Lee; Choong Y Ahn; Eun J Kim; Jong W Kwon; Sang G Kim; Suk J Chung; Chang-K Shim; Myung G Lee
Journal:  Biopharm Drug Dispos       Date:  2003-03       Impact factor: 1.627

View more
  9 in total

1.  Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

2.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

3.  Pharmacokinetics of itraconazole in diabetic rats.

Authors:  Unji Lee; Young H Choi; So H Kim; Byung K Lee
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

4.  Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2.

Authors:  Y H Choi; U Lee; B K Lee; M G Lee
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

5.  Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection.

Authors:  Julien P Maincent; Laura K Najvar; William R Kirkpatrick; Siyuan Huang; Thomas F Patterson; Nathan P Wiederhold; Jay I Peters; Robert O Williams
Journal:  Drug Dev Ind Pharm       Date:  2016-10-05       Impact factor: 3.225

6.  Pharmacokinetics and the Dermal Absorption of Bromochlorophene, a Cosmetic Preservative Ingredient, in Rats.

Authors:  Yong-Jae Lee; Hyang-Yeon Kim; Quynh-Lien Pham; Jung-Dae Lee; Kyu-Bong Kim
Journal:  Toxics       Date:  2022-06-16

7.  Preparation of Topical Itraconazole with Enhanced Skin/Nail Permeability and In Vivo Antifungal Efficacy against Superficial Mycosis.

Authors:  Laxman Subedi; Seung-Yub Song; Saurav Kumar Jha; Sung-Ho Lee; Rudra Pangeni; Kyo-Tan Koo; Beum Joon Kim; Seung-Sik Cho; Jin Woo Park
Journal:  Pharmaceutics       Date:  2021-04-27       Impact factor: 6.321

8.  Combinatory Treatment with Oseltamivir and Itraconazole Targeting Both Virus and Host Factors in Influenza A Virus Infection.

Authors:  Sebastian Schloer; Jonas Goretzko; Stephan Pleschka; Stephan Ludwig; Ursula Rescher
Journal:  Viruses       Date:  2020-06-29       Impact factor: 5.048

9.  Pharmacologically induced endolysosomal cholesterol imbalance through clinically licensed drugs itraconazole and fluoxetine impairs Ebola virus infection in vitro.

Authors:  Susann Kummer; Angelika Lander; Jonas Goretzko; Norman Kirchoff; Ursula Rescher; Sebastian Schloer
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 7.163

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.